Here are the 10-K annual reports from VolitionRx Limited (VNRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNRX filings page.
VolitionRx Limited filed Amendment No. 1 to its annual report to add detailed Part III information on directors, executive officers, governance, and compensation. The filing also explains a one-for-twenty reverse stock split effective April 28, 2026, and retroactively adjusts all share data. As of June 30, 2025, non‑affiliate common stock had an aggregate market value of $72,909,373, and as of April 28, 2026, there were 8,087,955 common shares outstanding. The amendment outlines committee structures, employment and consulting agreements, stock-based incentives, severance terms, and outstanding stock options and restricted stock units for key executives and directors.
VolitionRx Limited is a multi-national epigenetics company developing simple, cost‑effective blood tests for early detection and monitoring of cancer and NETosis‑related diseases in humans and animals. Its core pillars include Nu.Q® Vet, Nu.Q® NETs, Nu.Q® Discover, Nu.Q® Cancer and Capture‑PCR™/Capture‑Seq™ liquid biopsy technologies.
The company is commercializing the Nu.Q® Vet Cancer Test globally through partners such as Antech, IDEXX and Fujifilm Vet Systems, and has begun generating European revenue from its CE‑marked Nu.Q® NETs assay. Management estimates multi‑billion‑dollar annual total addressable markets across lung cancer, multi‑cancer early detection, sepsis, broader NETosis, companion animal cancer and pharma companion diagnostics.
VolitionRx remains deeply loss‑making, with an accumulated deficit of about $252.9 million as of December 31, 2025 and only $1.1 million in cash and cash equivalents. Auditors issued a “going concern” opinion, and the company highlights a need to raise additional capital and service secured convertible debt under Lind Notes, alongside material weaknesses in internal control and risks of NYSE American listing non‑compliance.